The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy

Authors

  • Christopher Freese Department of Radiation Oncology, University of Cincinnati Barrett Cancer Center, Cincinnati, OH, USA
  • Mickaela Sudhoff Department of Radiation Oncology, University of Cincinnati Barrett Cancer Center, Cincinnati, OH, USA
  • Luke Lewis Department of Radiation Oncology, University of Cincinnati Barrett Cancer Center, Cincinnati, OH, USA
  • Michael Lamba Department of Radiation Oncology, University of Cincinnati Barrett Cancer Center, Cincinnati, OH, USA
  • Jordan Kharofa Department of Radiation Oncology, University of Cincinnati Barrett Cancer Center, Cincinnati, OH, USA

DOI:

https://doi.org/10.1080/0284186X.2017.1377847

Abstract

No Abstract Available

Downloads

Download data is not yet available.

Downloads

Published

2018-05-04

How to Cite

Freese, C. ., Sudhoff, M., Lewis, L. ., Lamba, M. ., & Kharofa, J. . (2018). The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy. Acta Oncologica, 57(5), 683–686. https://doi.org/10.1080/0284186X.2017.1377847

Issue

Vol. 57 No. 5 (2018): Acta Oncologica

Section

Articles